Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mapi Pharma Ltd.

www.mapi-pharma.com

Latest From Mapi Pharma Ltd.

Mylan Prepares For US Trastuzumab Entry

Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.

Biosimilars Launches

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year

Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.

Deals Financing

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago. 

Biosimilars Generic Drugs

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago. 

Biosimilars Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
  • Therapeutic Areas
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Mapi - Pharma Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Mapi Pharma Ltd.
  • Senior Management
  • Ehud Marom, CEO
    Nir Bernstein, CFO
    Shai Rubnov, PhD, VP, R&D
    Alex Mogle, VP, Corp. Dev.
    Safi Landskroner , VP, Bus. Dev. & Reg. Affairs
  • Contact Info
  • Mapi Pharma Ltd.
    Phone: 73 7121213
    Weizmann Science Pk.
    16 Einstein St.
    P.O. Box 4113 Ness Ziona, 74140
    Israel
UsernamePublicRestriction

Register